Phoenix Biotechnology, Inc   Report issue

For profit Phase 2
Founded: San Antonio TX United States (2003)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2015
NCT02329717
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

pbi-05204 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1